Zealand Pharma

Glostrup, Denmark

Zealand Pharma

Glostrup, Denmark

Time filter

Source Type

Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim Copenhagen, May 11, 2017 - Zealand Pharma A/S ("Zealand") and Boehringer Ingelheim GmbH have demonstrated that the novel long-acting amylin analogue ZP4982 prevents the development of obesity in preclinical models, suggesting its potential use in treating obesity and obesity-related comorbidities. Zealand and Boehringer Ingelheim will jointly present these data at the Keystone Symposia 'Neuronal Control of Appetite, Metabolism and Weight/Gastrointestinal Control of Metabolism' on Friday May 12 in Copenhagen, Denmark. Worldwide, obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 600 million were obese.[i] Amylin is a pancreatic peptide hormone that, through its satiety signaling effects, inhibits food intake and holds potential as a novel anti-obesity therapy. Zealand and Boehringer Ingelheim have developed novel differentiated long-acting amylin analogues using a unique peptide approach, and Boehringer Ingelheim plans to advance a lead molecule into clinical testing this year. Adam Steensberg, Senior Vice President, Chief Medical and Development Officer of Zealand, comments: "Zealand has two collaborations with Boehringer Ingelheim and is excited to report progress on the amlyin program. Our amylin analogue, which has differentiation potential due to its long-acting profile, has shown significant metabolic benefits in preclinical obesity and diabetes models. We look forward to the initiation of clinical development of a lead molecule in 2017 to further explore its potential. We are impressed with the thoroughness and dedication of Boehringer Ingelheim - not only in relation to this long-acting amylin analogue, but also in relation to our partnership on the long-acting glucagon/GLP-1 analogue. These are important projects for Zealand, with significant milestone payments and royalties potentially contributing to growing revenue in the future." Under the terms of the two agreements, Boehringer Ingelheim funds all research, development and commercialization activities. Zealand is eligible to receive license and milestone payments as follows: For further information, please contact: About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases. 2 Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua(TM) 100/33 in the U.S. and has been approved as Suliqua(TM) in Europe. Zealand's proprietary pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for improved hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics. Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.


Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim Copenhagen, May 11, 2017 - Zealand Pharma A/S ("Zealand") and Boehringer Ingelheim GmbH have demonstrated that the novel long-acting amylin analogue ZP4982 prevents the development of obesity in preclinical models, suggesting its potential use in treating obesity and obesity-related comorbidities. Zealand and Boehringer Ingelheim will jointly present these data at the Keystone Symposia 'Neuronal Control of Appetite, Metabolism and Weight/Gastrointestinal Control of Metabolism' on Friday May 12 in Copenhagen, Denmark. Worldwide, obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 600 million were obese.[i] Amylin is a pancreatic peptide hormone that, through its satiety signaling effects, inhibits food intake and holds potential as a novel anti-obesity therapy. Zealand and Boehringer Ingelheim have developed novel differentiated long-acting amylin analogues using a unique peptide approach, and Boehringer Ingelheim plans to advance a lead molecule into clinical testing this year. Adam Steensberg, Senior Vice President, Chief Medical and Development Officer of Zealand, comments: "Zealand has two collaborations with Boehringer Ingelheim and is excited to report progress on the amlyin program. Our amylin analogue, which has differentiation potential due to its long-acting profile, has shown significant metabolic benefits in preclinical obesity and diabetes models. We look forward to the initiation of clinical development of a lead molecule in 2017 to further explore its potential. We are impressed with the thoroughness and dedication of Boehringer Ingelheim - not only in relation to this long-acting amylin analogue, but also in relation to our partnership on the long-acting glucagon/GLP-1 analogue. These are important projects for Zealand, with significant milestone payments and royalties potentially contributing to growing revenue in the future." Under the terms of the two agreements, Boehringer Ingelheim funds all research, development and commercialization activities. Zealand is eligible to receive license and milestone payments as follows: For further information, please contact: About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases. 2 Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua(TM) 100/33 in the U.S. and has been approved as Suliqua(TM) in Europe. Zealand's proprietary pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for improved hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics. Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.


Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim Copenhagen, May 11, 2017 - Zealand Pharma A/S ("Zealand") and Boehringer Ingelheim GmbH have demonstrated that the novel long-acting amylin analogue ZP4982 prevents the development of obesity in preclinical models, suggesting its potential use in treating obesity and obesity-related comorbidities. Zealand and Boehringer Ingelheim will jointly present these data at the Keystone Symposia 'Neuronal Control of Appetite, Metabolism and Weight/Gastrointestinal Control of Metabolism' on Friday May 12 in Copenhagen, Denmark. Worldwide, obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 600 million were obese.[i] Amylin is a pancreatic peptide hormone that, through its satiety signaling effects, inhibits food intake and holds potential as a novel anti-obesity therapy. Zealand and Boehringer Ingelheim have developed novel differentiated long-acting amylin analogues using a unique peptide approach, and Boehringer Ingelheim plans to advance a lead molecule into clinical testing this year. Adam Steensberg, Senior Vice President, Chief Medical and Development Officer of Zealand, comments: "Zealand has two collaborations with Boehringer Ingelheim and is excited to report progress on the amlyin program. Our amylin analogue, which has differentiation potential due to its long-acting profile, has shown significant metabolic benefits in preclinical obesity and diabetes models. We look forward to the initiation of clinical development of a lead molecule in 2017 to further explore its potential. We are impressed with the thoroughness and dedication of Boehringer Ingelheim - not only in relation to this long-acting amylin analogue, but also in relation to our partnership on the long-acting glucagon/GLP-1 analogue. These are important projects for Zealand, with significant milestone payments and royalties potentially contributing to growing revenue in the future." Under the terms of the two agreements, Boehringer Ingelheim funds all research, development and commercialization activities. Zealand is eligible to receive license and milestone payments as follows: For further information, please contact: About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases. 2 Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua(TM) 100/33 in the U.S. and has been approved as Suliqua(TM) in Europe. Zealand's proprietary pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for improved hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics. Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.


Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim Copenhagen, May 11, 2017 - Zealand Pharma A/S ("Zealand") and Boehringer Ingelheim GmbH have demonstrated that the novel long-acting amylin analogue ZP4982 prevents the development of obesity in preclinical models, suggesting its potential use in treating obesity and obesity-related comorbidities. Zealand and Boehringer Ingelheim will jointly present these data at the Keystone Symposia 'Neuronal Control of Appetite, Metabolism and Weight/Gastrointestinal Control of Metabolism' on Friday May 12 in Copenhagen, Denmark. Worldwide, obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 600 million were obese.[i] Amylin is a pancreatic peptide hormone that, through its satiety signaling effects, inhibits food intake and holds potential as a novel anti-obesity therapy. Zealand and Boehringer Ingelheim have developed novel differentiated long-acting amylin analogues using a unique peptide approach, and Boehringer Ingelheim plans to advance a lead molecule into clinical testing this year. Adam Steensberg, Senior Vice President, Chief Medical and Development Officer of Zealand, comments: "Zealand has two collaborations with Boehringer Ingelheim and is excited to report progress on the amlyin program. Our amylin analogue, which has differentiation potential due to its long-acting profile, has shown significant metabolic benefits in preclinical obesity and diabetes models. We look forward to the initiation of clinical development of a lead molecule in 2017 to further explore its potential. We are impressed with the thoroughness and dedication of Boehringer Ingelheim - not only in relation to this long-acting amylin analogue, but also in relation to our partnership on the long-acting glucagon/GLP-1 analogue. These are important projects for Zealand, with significant milestone payments and royalties potentially contributing to growing revenue in the future." Under the terms of the two agreements, Boehringer Ingelheim funds all research, development and commercialization activities. Zealand is eligible to receive license and milestone payments as follows: For further information, please contact: About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases. 2 Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua(TM) 100/33 in the U.S. and has been approved as Suliqua(TM) in Europe. Zealand's proprietary pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for improved hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics. Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.


News Article | May 17, 2017
Site: globenewswire.com

Zealand reports results for the first three months of 2017 (unaudited) Copenhagen, May 17, 2017 - Zealand Pharma A/S ("Zealand") (Company reg. No. 20 04 50 78) announces financial results in line with guidance and continued positive progress for its product portfolio and business for the three-month period from January 1 to March 31, 2017. Financial results for the first three months of 2017 Business highlights for the first three months of 2017 Business highlights for the period thereafter Britt Meelby Jensen, President and CEO of Zealand, commented on the quarter: "The first quarter of 2017 saw a good start to an important year for Zealand, with financial results as expected. A major milestone was the U.S. launch of Soliqua®100/33 by Sanofi, followed this month by the first launch in the EU. Sanofi has already secured coverage for 34% of commercially insured patients. With Soliqua® 100/33 as the first marketed GLP-1/insulin combination in the U.S., Sanofi continues to educate physicians and expand insurance coverage". "In addition, we report strong progress on our clinical programs. We look forward to Phase 2 results for glepaglutide, our long-acting GLP-2 analogue for short bowel syndrome, by the end of June, and we plan to report dasiglucagon Phase 2a results this quarter, supporting its potential use in a dual-chamber pump. We are excited to expand our dasiglucagon franchise to include orphan indications, following a positive opinion in the EU for dasiglucagon for the treatment of congenital hyperinsulinism". "Finally, I would like to highlight the announcement of amylin as the biological target in one of our partnership programs with Boehringer Ingelheim addressing obesity, and we look forward to the advancement into clinical testing later in 2017." Conference call today at 4 p.m. CET Zealand's management will be hosting a conference call today at 4 p.m. CET to present the Q1 results. Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen, Executive Vice President and Chief Financial Officer Mats Blom and Executive Vice President and Chief Medical and Development Officer Adam Steensberg. The presentation will be followed by a Q&A session. The conference call will be conducted in English, and the dial-in numbers are: A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, http://edge.media-server.com/m/p/iuasout3, also accessible on the Investor section of Zealand's website (www.zealandpharma.com). Participants are advised to register for the webcast approximately 10 minutes before the start. A recording of the event will be made available on the Investor section of Zealand's website after the call. For further information, please contact: About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates focusing on specialty gastrointestinal and metabolic diseases. 2 Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and as Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua®100/33 in the U.S. and has been approved as Suliqua® in Europe and launched in the Netherlands. Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for improved hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics. Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.


Aktiekapitalen i Zealand Pharma A/S vil med virkning fra den 20. april 2017 blive forhøjet på Nasdaq Copenhagen. Optagelse til handel og officiel notering af nye aktier vil ske i nedenstående ISIN. ISIN: DK0060257814 ------------------------------------------------------- Navn: Zealand Pharma ------------------------------------------------------- Mængde før ændring: 26.151.865 stk. (26.151.865 kr.) ----------


The share capital of Zealand Pharma has been increased. The admittance to trading and official listing of new shares will take effect as per 20 April 2017 in the ISIN below. For further information, please contact: Asta Jepsen, Surveillance, tel. +45 33 93 33 66


Leading Peptides Expert Explores the Role of LC-MS in Drug Development and Delivery New Interview Released with Ferring’s Peptide and LC-MS expert in the lead to SMi's Peptides 2017 event. London, United Kingdom, May 04, 2017 --( With over 15 years of expertise in peptides, Jörgen will bring insights into using Liquid Chromatography and Mass Spetrometry as a key technique to understanding the fate of impurities using examples from Ferring's synthetic therapeutic peptide portfolio. In the lead to the event, the SMi Group spoke to Jörgen to get his perspective on the current peptides landscape in relation to his presentation. "Today it is very important to have complete understanding of the synthesis and fate of impurities, from starting material to final drug substance (API) to be able to make safe drugs for the patient, make robust processes, and of course, to get authority approval of our new drug products. "The take home message is that LC-MS/MS is necessary in the field of making pharmaceuticals from synthetic peptides, which most people are aware of today. I will show with several examples that LC-MS is a key instrument in understanding the fate of impurities during the whole process of making a drug, from starting material to final drug product. I hope that I can convince people, if they not already are doing it, that investing time in fate of impurities study will be a help in developing more robust processes and safer drugs for the patients. It has also been very important to have this knowledge when answering questions from authorities. Another thing I would like people to get from my presentation is that separation.” The full interview is available to read on www.peptidesevent.com/prcom. The line-up joining Jörgen at Peptides 2017 includes an elite group of international experts from UCB, Novartis, Boehringer-Ingelheim, Bristol-Myers Squibb, Nestle Skin Health, Sanofi, Zealand Pharma, Ipsen and more. For further details or to register, visit the event website at www.peptidesevent.com/prcom. 4th Peptides Event 6-7 July 2017 Holiday Inn Kensington Forum, London UK www.peptidesevent.com/prcom For delegate registration enquiries, contact Fateja Begum on fbegum@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk. About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, May 04, 2017 --( PR.com )-- Jörgen Kjellgren Sjögren, Senior Research Scientist at Ferring Pharmaceuticals, has joined the expert speaker lineup for SMi Group’s 4th Peptides Event in July.With over 15 years of expertise in peptides, Jörgen will bring insights into using Liquid Chromatography and Mass Spetrometry as a key technique to understanding the fate of impurities using examples from Ferring's synthetic therapeutic peptide portfolio.In the lead to the event, the SMi Group spoke to Jörgen to get his perspective on the current peptides landscape in relation to his presentation."Today it is very important to have complete understanding of the synthesis and fate of impurities, from starting material to final drug substance (API) to be able to make safe drugs for the patient, make robust processes, and of course, to get authority approval of our new drug products."The take home message is that LC-MS/MS is necessary in the field of making pharmaceuticals from synthetic peptides, which most people are aware of today. I will show with several examples that LC-MS is a key instrument in understanding the fate of impurities during the whole process of making a drug, from starting material to final drug product. I hope that I can convince people, if they not already are doing it, that investing time in fate of impurities study will be a help in developing more robust processes and safer drugs for the patients. It has also been very important to have this knowledge when answering questions from authorities. Another thing I would like people to get from my presentation is that separation.”The full interview is available to read on www.peptidesevent.com/prcom.The line-up joining Jörgen at Peptides 2017 includes an elite group of international experts from UCB, Novartis, Boehringer-Ingelheim, Bristol-Myers Squibb, Nestle Skin Health, Sanofi, Zealand Pharma, Ipsen and more.For further details or to register, visit the event website at www.peptidesevent.com/prcom.4th Peptides Event6-7 July 2017Holiday Inn Kensington Forum, London UKwww.peptidesevent.com/prcomFor delegate registration enquiries, contact Fateja Begum on fbegum@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk.About SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


Nestle Skin Health to Discuss Peptidomimetic Inhibitors at the 4th Peptides Event London, United Kingdom, April 21, 2017 --( Speaking on Day 1 of the conference, Craig’s presentation will touch on issues facing medicinal chemistry looking at topical administration of actives, and focus on the numerous synthetic issues encountered during an arduous journey to find selective and stable inhibitors of Caspase I. In an interview with SMi Group, Craig said "Historically, peptides have always given very strong leads for drug molecules and also as efficient delivery vehicles and biomaterials in the form of hydrogels for example. With the developments in general synthesis efficiency and diversification points, I can see peptides being a more and more important player in drug discovery, formulation and biomaterial applications in the future." Asked about his views on the current peptides landscape, he said “I think it’s a great time for peptides with demand from all corners of the industry including cosmetics! The advances in basic peptide assembly and stabilisation of bioactive peptidic sequences to metabolism through chemical modification, conjugation or stapling through latest advances in synthetic organic chemistry have been outstanding thus opening new avenues for drug discovery.” The full interview is available to read on www.peptidesevent.com/prcom. The line-up joining Craig at Peptides 2017 includes an elite group of international experts from UCB, Novartis, Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi, Zealand Pharma, Ipsen and more. For further details or to register, visit the event website at www.peptidesevent.com/ 4th Peptides Event 6-7 July 2017 Holiday Inn Kensington Forum, London UK www.peptidesevent.com/xxx For delegate registration enquiries, contact Fateja Begum on fbegum@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk. About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, April 21, 2017 --( PR.com )-- Nestlé Skin Health Head of Research Synthesis, Craig Harris, has joined the speaker line-up for SMi Group’s 4th Peptides Event, which takes place on the 6th and 7th of July this year. Craig has been leading synthesis in the pharmaceutical industry for 20 years on a diverse range of projects in the oncology field and more recently in the dermatology and aesthetic & corrective fields.Speaking on Day 1 of the conference, Craig’s presentation will touch on issues facing medicinal chemistry looking at topical administration of actives, and focus on the numerous synthetic issues encountered during an arduous journey to find selective and stable inhibitors of Caspase I.In an interview with SMi Group, Craig said "Historically, peptides have always given very strong leads for drug molecules and also as efficient delivery vehicles and biomaterials in the form of hydrogels for example. With the developments in general synthesis efficiency and diversification points, I can see peptides being a more and more important player in drug discovery, formulation and biomaterial applications in the future."Asked about his views on the current peptides landscape, he said “I think it’s a great time for peptides with demand from all corners of the industry including cosmetics! The advances in basic peptide assembly and stabilisation of bioactive peptidic sequences to metabolism through chemical modification, conjugation or stapling through latest advances in synthetic organic chemistry have been outstanding thus opening new avenues for drug discovery.”The full interview is available to read on www.peptidesevent.com/prcom.The line-up joining Craig at Peptides 2017 includes an elite group of international experts from UCB, Novartis, Boehringer-Ingelheim, Bristol-Myers Squibb, Sanofi, Zealand Pharma, Ipsen and more.For further details or to register, visit the event website at www.peptidesevent.com/4th Peptides Event6-7 July 2017Holiday Inn Kensington Forum, London UKwww.peptidesevent.com/xxxFor delegate registration enquiries, contact Fateja Begum on fbegum@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk.About SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


Short Bowel Syndrome Diagnostics and Treatment Market by Test types, Drug Classes, Trends, and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc. Short Bowel Syndrome Diagnostics and Treatment Market by Test Type (Complete Blood Test, Fecal Fat Test, Imaging Tests – X-Ray, Ct Scan, Others), and Drug Class (GLP-2, Growth Hormone, L-Glutamine, Others) and Forecast 2017-2021 Maryland Heights, MO, May 04, 2017 --( Browse Short Bowel Syndrome Diagnostics and Treatment Market by Test Type (Complete Blood Test, Fecal Fat Test, Imaging Tests – X-Ray, Ct Scan, Others), and Drug Class (GLP-2, Growth Hormone, L-Glutamine, Others) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/short-bowel-syndrome-diagnostics-treatment-market/ The global short bowel syndrome diagnostics and treatment market segmentation is based on test type (complete blood test, fecal fat test, imaging tests such as X-ray, CT scan, others) and drug class (GLP-2, growth hormones, and L-glutamine, others). The global short bowel syndrome diagnostics and treatment market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global short bowel syndrome diagnostics and treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global short bowel syndrome diagnostics and treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. Major players operating in the global short bowel syndrome diagnostics and treatment market and included in this report are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio and Company, Inc., Shire plc, and Zealand Pharma A/S. 1. Test Type 1.1. Complete Blood Test 1.2. Fecal Fat Test 1.3. Imaging Tests 1.3.1. X-ray 1.3.2. CT Scan 1.4. Others 2. Drug Class 2.1. GLP-2 2.2. Growth Hormones 2.3. L-Glutamine 2.4. Others 3. Geography 3.1. North America (U.S., Canada) 3.2. Latin America (Brazil, Mexico, Rest of LA) 3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 3.4. Asia Pacific (Japan, China, India, Rest of APAC) 3.5. Rest of the World 4. Company Profiles 4.1. Ardelyx, Inc. 4.2. Emmaus Life Sciences, Inc. 4.3. GLyPharma Therapeutic, Inc. 4.4. Merck KGaA 4.5. Naia Pharmaceuticals, Inc. 4.6. Nutrinia Ltd. 4.7. OxThera 4.8. Sancilio and Company, Inc. 4.9. Shire plc 4.10. Zealand Pharma A/S To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/short-bowel-syndrome-diagnostics-treatment-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, May 04, 2017 --( PR.com )-- Short bowel syndrome (SBS) is a group of problems related to poor absorption of nutrients. Short bowel syndrome typically occurs in people who have had at least half of their small intestine removed and sometimes all or part of their large intestine removed, significant damage of the small intestine, poor motility, or movement, inside the intestines. diagnoses short bowel syndrome based on a medical and family history, a physical exam, blood tests, fecal fat tests, an x-ray of the small and large intestines, upper gastrointestinal (GI) series, computerized tomography (CT) scan, etc. Treatment will often include medications, and in some instances surgery. General medications to treat short bowel syndrome include antibiotics to prevent bacterial overgrowth, H2 blockers to treat too much gastric acid secretion, proton pump inhibitors to treat too much gastric acid secretion, choleretic agents to improve bile flow and prevent liver disease, bile-salt binders to decrease diarrhea, anti-secretin agents to reduce gastric acid in the intestine, hypomotility agents to increase the time it takes food to travel through the intestines, leading to increased nutrient absorption, growth hormones to improve intestinal absorption, teduglutide to improve intestinal absorption. Typically, the SBS treatment regime includes Teduglutide (Gattex) hormone, L-glutamine, or Somatropin (Zorbtive), a human growth hormone.Browse Short Bowel Syndrome Diagnostics and Treatment Market by Test Type (Complete Blood Test, Fecal Fat Test, Imaging Tests – X-Ray, Ct Scan, Others), and Drug Class (GLP-2, Growth Hormone, L-Glutamine, Others) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/short-bowel-syndrome-diagnostics-treatment-market/The global short bowel syndrome diagnostics and treatment market segmentation is based on test type (complete blood test, fecal fat test, imaging tests such as X-ray, CT scan, others) and drug class (GLP-2, growth hormones, and L-glutamine, others).The global short bowel syndrome diagnostics and treatment market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global short bowel syndrome diagnostics and treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global short bowel syndrome diagnostics and treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.Major players operating in the global short bowel syndrome diagnostics and treatment market and included in this report are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio and Company, Inc., Shire plc, and Zealand Pharma A/S.1. Test Type1.1. Complete Blood Test1.2. Fecal Fat Test1.3. Imaging Tests1.3.1. X-ray1.3.2. CT Scan1.4. Others2. Drug Class2.1. GLP-22.2. Growth Hormones2.3. L-Glutamine2.4. Others3. Geography3.1. North America (U.S., Canada)3.2. Latin America (Brazil, Mexico, Rest of LA)3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)3.4. Asia Pacific (Japan, China, India, Rest of APAC)3.5. Rest of the World4. Company Profiles4.1. Ardelyx, Inc.4.2. Emmaus Life Sciences, Inc.4.3. GLyPharma Therapeutic, Inc.4.4. Merck KGaA4.5. Naia Pharmaceuticals, Inc.4.6. Nutrinia Ltd.4.7. OxThera4.8. Sancilio and Company, Inc.4.9. Shire plc4.10. Zealand Pharma A/STo request Table of Contents and Sample Pages of this report visit:https://www.ihealthcareanalyst.com/report/short-bowel-syndrome-diagnostics-treatment-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com

Loading Zealand Pharma collaborators
Loading Zealand Pharma collaborators